Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome.
about
Which anticholinergic drug for overactive bladder symptoms in adultsPersistence and compliance with medication management in the treatment of overactive bladderFlexible dosing with fesoterodine 4 and 8 mg: a systematic review of data from clinical trialsDoes fesoterodine have a role in the treatment of poorly managed patients with overactive bladder?Review of fesoterodineAdverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approachElectronic bladder diaries of differing duration versus a paper diary for data collection in overactive bladder.Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: a decision-tree model.Impact of fesoterodine on quality of life: pooled data from two randomized trials.A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder.Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in SpainModeling dose-response relationships of the effects of fesoterodine in patients with overactive bladderBehavioral treatment of insomnia: also effective for nocturia.The overlap of interstitial cystitis/painful bladder syndrome and overactive bladderEfficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ERNeurogenic detrusor overactivity is associated with decreased expression and function of the large conductance voltage- and Ca(2+)-activated K(+) channelsCardiac effects of muscarinic receptor antagonists used for voiding dysfunction.Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects.Pharmacologic treatment for urgency-predominant urinary incontinence in women diagnosed using a simplified algorithm: a randomized trialEffects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study.Role of fesoterodine in the treatment of overactive bladder.Nocturia: a non-specific but important symptom of urological disease.Basic mechanisms of urgency: roles and benefits of pharmacotherapyFesoterodine for the treatment of urinary incontinence and overactive bladder.Fesoterodine for the treatment of overactive bladder.Fesoterodine for overactive bladder: A review of the literature.Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature.The evaluation and treatment of nocturia: a consensus statement.Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder.Fesoterodine in randomised clinical trials: an updated systematic clinical review of efficacy and safety.Nocturia Think Tank: focus on nocturnal polyuria: ICI-RS 2011.Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females.Nocturia: current concepts and future perspectives.Current pharmacotherapy of nocturia.Cardiovascular effects of antimuscarinic agents in overactive bladder.Evaluation of fesoterodine fumarate for the treatment of an overactive bladder.Fesoterodine fumarate and the oxybutynin ring for the treatment of urinary incontinence in women.Cost effectiveness of fesoterodine and tolterodine for the treatment of overactive bladder with urge urinary incontinence in Spain and Finland.Etiology, evaluation, and management of nocturia in elderly men and women.Review of the efficacy and safety of fesoterodine for treating overactive bladder and urgency urinary incontinence in elderly patients.
P2860
Q24203880-7F3F84B0-CBEB-4479-9D99-18DDC17A85EBQ26765014-93D043A2-E4EC-4354-A4D7-4BC61EBC663BQ26827108-4A9BEDC3-70B7-413E-A95D-13FB1CB83F58Q27000698-A2DB83DC-EB90-411F-9692-44222A3C8989Q28239495-93A1F5DB-4E89-419C-B967-B90A495AF332Q28742444-6EDE58BB-20CE-43CE-821A-4E392F0A8047Q30980428-2569DEC7-1D29-49FA-A26A-D47399814442Q31013378-B69A335E-79FE-4D6C-86DF-C4F78387A595Q31159751-66BBA03E-7867-4659-A5F4-5BE58380D4C6Q33485538-C299F02E-E01D-4B2D-9029-2C5F92989651Q33588346-E6EF0C0F-174E-410C-B2CA-1A62EDECADA0Q33665585-A9A8165E-CADC-4AC6-8FB9-8FD47D4AEBE2Q33748111-5BB861D9-2133-417B-B689-C6DE4704CFFEQ34492081-8FC1036F-C1C8-4BFB-AA7E-15BFE2B8452AQ34693256-0927633E-B4A0-4856-89C8-41911E72DE66Q34826716-8C3EEF15-A3CC-4008-AE29-A621E65F05AFQ35183599-0BE3E10F-F4C7-4AD9-BFEB-E15C4FDFF5ECQ35183627-CC475BE9-ACE7-4D1D-8824-48BA32871D61Q36603287-0EF3D5F3-9F73-435D-B0AC-44600FD9A0B0Q37250582-24263548-067A-49BA-A6B9-1429296E938DQ37283542-3C6D54A3-CF4D-477C-A9E2-7C9ECE4317CFQ37396037-9441D2C3-DEA0-49D8-A651-7715E96DBF1AQ37428717-78DBF05F-7FFB-4D6E-9A4C-D28526717582Q37429813-7574CB41-D135-47B4-84DA-B7BF57A82801Q37634191-55B6EC91-042D-43D4-B8F3-D2AA2A241E0CQ37672074-D990FA76-9170-41ED-AA03-43EAA85EBD2CQ37864717-72F67991-9EA5-4044-B11C-B92DC07F42F4Q37890031-134BCA9E-FFCB-4A11-87C3-37B76204BEC3Q37914849-075F34A7-8754-40AB-96FC-4539098E0E09Q37992884-A55E4DFF-C544-4EBD-A6DD-16D0040ABF7FQ37993502-D6378233-26CB-4FF1-8CBA-81FC1884E654Q38032608-633A671A-5057-4BF1-A252-FA8DA705AEFAQ38049167-BA6E5878-65E5-4F17-A6E4-760E43CF9D7DQ38095986-AFB415F5-CBEE-451D-A2B2-9E2209B007FAQ38116972-A1965F73-8CB4-40D2-AB47-E3ED9EF8BAF8Q38160883-3DEED567-EF72-493D-96E1-49C71BFFFC35Q38173919-D550AB1B-5AD2-4836-B301-01CD94E1D0E3Q38190923-DF69D61C-8044-46FD-B4FF-6D856E647223Q38200832-CAE95272-A504-4F13-ACC3-3C1007698F69Q38352217-D2229EB5-F029-4E2C-913C-CC05AED6E524
P2860
Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome.
@en
Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome.
@nl
type
label
Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome.
@en
Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome.
@nl
prefLabel
Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome.
@en
Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome.
@nl
P2093
P1476
Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome.
@en
P2093
Cornelia Haag-Molkenteller
Hans-Theo Forst
Joseph Wang
Marina Brodsky
Peter K Sand
Tamara Bavendam
Ute Massow
P304
P356
10.1016/J.JURO.2007.08.033
P407
P577
2007-10-15T00:00:00Z